GlassScriptPhysician profile
Lindsey B Barouh
NPI 1992091367
$3,369.66
in general payments reported to CMS, 2019-2025
21 companies · $867 in 2025
The $867 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $89.91 · 2021: $495 · 2022: $487 · 2023: $660 · 2024: $485 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,089.38 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Sun Pharmaceutical Industries INC. | $373.65 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $357.96 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $311.54 | 2022-2025 | Argos |
| Allergan, INC. | $295.54 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $153.08 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $148.04 | 2019 | |
| Aerie Pharmaceuticals, INC. | $147.65 | 2021 | |
| Apellis Pharmaceuticals, INC. | $83.45 | 2023-2024 | Syfovre |
| Novartis Pharmaceuticals Corporation | $60.07 | 2020-2021 | |
| Visioneering Technologies, INC. | $51.89 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.10 | 2019-2021 | |
| Harrow Eye, LLC | $45.23 | 2024 | Vevye |
| Sight Sciences, INC. | $41.89 | 2019 | |
| Bausch & Lomb Americas INC. | $39.06 | 2023-2024 | Xiidra, Miebo, Vyzulta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $32.20 | 2022 | |
| Amgen INC. | $23.84 | 2024 | Tepezza |
| Rxsight INC | $23.50 | 2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Rayner Intraocular Lenses Limited | $21.59 | 2023 | Rayone Emv, Rayone Aspheric, Omidria |
| Kala Pharmaceuticals, INC. | $12.89 | 2021 | |
| Eyevance Pharmaceuticals LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Barouh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.